APA (7th ed.) Citation

Smith, P. F., Ogundele, A., Forrest, A., Wilton, J., Salzwedel, K., Doto, J., . . . Martin, D. E. (2007). Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 51(10), 3574-3581. https://doi.org/10.1128/aac.00152-07

Chicago Style (17th ed.) Citation

Smith, Patrick F., Abayomi Ogundele, Alan Forrest, John Wilton, Karl Salzwedel, Judy Doto, Graham P. Allaway, and David E. Martin. "Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) Against Human Immunodeficiency Virus Infection." Antimicrobial Agents and Chemotherapy 51, no. 10 (2007): 3574-3581. https://doi.org/10.1128/aac.00152-07.

MLA (9th ed.) Citation

Smith, Patrick F., et al. "Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) Against Human Immunodeficiency Virus Infection." Antimicrobial Agents and Chemotherapy, vol. 51, no. 10, 2007, pp. 3574-3581, https://doi.org/10.1128/aac.00152-07.